|Table of Contents|

The clinical efficacy analysis of induction chemotherapy plus late course hyperfractionation radiotherapy in the treatment of ulcerative esophageal carcinoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2019 06
Page:
964-969
Research Field:
Publishing date:

Info

Title:
The clinical efficacy analysis of induction chemotherapy plus late course hyperfractionation radiotherapy in the treatment of ulcerative esophageal carcinoma
Author(s):
Zhai Xiju
Department of Radiotherapy,Taian Tumor Hospital,Shandong Taian 271000,China.
Keywords:
esophageal carcinoma; hyperfractionation radiotherapy; chemotherapy; ulcerative esophageal carcinoma
PACS:
R735.1
DOI:
10.3969/j.issn.1672-4992.2019.06.014
Abstract:
Objective:The clinical Efficacy Analysis of induction chemotherapy plus late course hyperfractionation radiotherapy in the treatment of ulcerative esophageal carcinoma.Methods:Analysis of the clinical efficacy of induction chemotherapy plus late course hyperfractionation radiotherapy in the treatment of ulcerative esophageal carcinoma patient whoes in the Radiotherapy Dept.in our hospital during April 2009 and August 2012,a total of 148 cases.It was divided into observation group of 79 cases (induction chemotherapy+late hyperfractionation radiotherapy group) and control group of 69 cases(induction chemotherapy+conventional fractionated radiotherapy group) using random number grouping.Chemotherapy:PF scheme 2 cycle.Radiotherapy methods:6 MV-X-ray,conformal IMRT in vitro irradiation.Observation group:The initial radiotherapy divisional dose is 1.6 Gy each time at the first and second week,the divisional dose is 1.8 Gy each time at the third and fourth week,5 times a week,the total dose is 34 Gy/20 times at the first 4 weeks.Late course hyperfractionation radiotherapy ivisional dose is 1.25 Gy each time,2 times a day,interval time between 2 times≥ 6 h,total dose is 30 Gy/24 times/2.5 weeks.The total dose is 64 Gy.Control group:conventional fractionated radiotherapy,5 times a week,the divisional dose is 2.0 Gy each time,total dose is 64 Gy/32 times/6.5 weeks.Results:The actual completion of treatment:the observation group/control group is 92.4%/78.3%,the difference was statistically significant.Ulcer healing rate:The observation group/control group is 92.4%/82.6%,the difference was statistically significant.The effective rate (CR+PR) of the observation group/control group was 92.4%/79.7%,the difference between the two groups was statistically significant.The 1,3 and 5-year local control rates in observation group and control group were 82.3%/59.4%,54.4%/43.5% and 36.7%/14.5% respectively,the survival rate of 1,3 and 5-year was 79.7%/68.1%,39.2%/29.0%,15.2%/8.7%,especially the local control rate of 1 and 5-year and survival rate of 5-year of observation group was significantly better than the control group,the difference was statistically significant.Side effects:Acute mucosal reaction,especially Ⅰ-Ⅱ grade,the incidence of observation group was significantly higher than that of the control group (P＜0.01),the difference was statistically significant.Advanced radiation injury was mainly esophageal stenosis,the incidence of observation group was significantly lower than the control group:Ⅰ-Ⅱ grade is 20.3%/69.6%,Ⅲ grade is 0/11.6%(P<0.01),the difference was statistically significant.Conclusion:The treatment of inducing chemotherapy for 2 cycles+initial low-dose radiotherapy+late course hyperfractionation radiotherapy+adjuvant chemotherapy 2 weeks can reduce the risk of esophageal perforation bleeding and the incidence of esophageal stenosis,and not significantly increase the side effects.This approach deserves further clinical study.

References:

［1］ Li J.Tumor medical diagnosis and treatment strategy ［M］.ShangHai.Shanghai:Scientific & Technical Publishers,2017:314.［李进.肿瘤内科诊治策略［M］.上海：上海科学技术出版社,2017:314.］
［2］Zhou JC.Practical oncology ［M］.Beijing:People's Medical Publishing House,1998:24-32.［周际昌.实用肿瘤内科学［M］.北京:人民卫生出版社,1998:24-32.］
［3］Li J.Tumor medical diagnosis and treatment strategy ［M］.Shanghai:Shanghai Scientific & Technical Publishers,2017:57.［李进.肿瘤内科诊治策略［M］.上海：上海科学技术出版社,2017:57.］
［4］Shi XH.Modern radiation oncology ［M］.Shanghai:Fudan University Press,Shanghai Medical University Press,2001:347-369.［施学辉.现代放射肿瘤学［M］.上海:复旦大学出版社、上海医科大学出版社,2001:347-369.］
［5］Xie L,Yao WQ,Shi XH.Unconventional radiotherapy of esophageal cancer ［J］.Chinese Journal of Radiation Oncology,1996,5(2)：140-142.［谢立,姚伟强,施学辉.食管癌的非常规分割放疗［J］.中华放射肿瘤学杂志,1996,5(2)：140-142.］
［6］Shi XH.Progress of radiotherapy for esophageal cancer ［J］.China Cancer,1999,8(4):169-172.［施学辉.食管癌放射治疗进展［J］.中国肿瘤,1999,8(4):169-172.］
［7］LuoYX,He AB,Long ZX,et al.Concurrent IMRT hyperfraction radiochemotherapy combined with adjuvant chemotherapy on elderly patients with locally advanced esophageal cancer［J］.Cancer Research on Prevention and Treatment,2015,42(8):814-817.［罗云秀,何安兵,龙志雄,等.超分割调强同步放化疗及辅助化疗治疗老年局部晚期食管癌的临床观察［J］.肿瘤防治研究,2015.42(8):814-817.］
［8］Sun JY,Guo ZL.Survival situation of surgical treatment of stage esophageal cancer patients［J］.China Journal of Modern Medicine 2017,27(15):87-91.［孙嘉阳,郭占林.外科治疗Ⅲ期食管癌患者的生存状况研究［J］.中国现代医学杂志,2017,27(15):87-91.］
［9］ Li XL,Shi XH.Study of phase Il of continuous accelerated hyperfractionated radiotherapy on esophageal carcinoma ［J］.Chinese Journal of Radiation Oncology,2011,20(6):477-478.［李晓丽,施学辉.食管癌三维适形全程加速超分割Ⅱ研究［J］.中华放射肿瘤学杂志,2011,20(6):477-478.］
［10］ Zhang LP,Li Q,Liu HX.An Analysis of conventional radiotherapy and late-course hyperfractionated radiotherapy for esophageal canner ［J］.Journal of Chinese Oncology,2013,19(11):903-904.［张丽萍,李强,刘化新.常规与后程超分割放疗治疗食管癌的疗效分析［J］.肿瘤学杂志,2013,19(11):903-904.］
［11］Liang GH，Wu JH,Ling ZQ.Clinical efficacy a hyperfractionated radiotherapy for esophageal carcinomand safty of different ［J］.The Practical Journal of Cancer,2014,29(12):1566-1568.［梁国华,吴建华,凌志琴.不同超分割放疗食管癌的临床疗效及安全性对比［J］.实用癌症杂志,2014,29(12):1566-1568.］
［12］Liu LH,Cai JD,Liu YQ,et al.Influence of late course accelerated fractionated irradiation with weekly nedaplatin combined with extracorporeal high-frequency hyperthermia on the effect and survival rate of patients with locally advanced esophageal cancer［J］.China Medical Herald,2017,14(11):87-90.［刘丽华,蔡君东,刘艳琴,等.周剂量奈达铂同步后程加速超分割放疗联合体外高频热疗对局部晚期食管癌患者疗效及生存率的影响［J］.中国医药导报,2017,14(11):87-90.］
［13］Li YJ.An analysis of late-course accelerated hyperfractionated radiotherapy combined with TP chemotherapy for esophageal canner［J］.Guangxi Medical Journal,2014,36(1):99-101.［李永杰.后程加速超分割放疗同步TP方案治疗食管癌疗效分析［J］.广西医学,2014,36(1):99-101.］
［14］Liu XF,Wang XH,ZHang QN,et al.Late course accelerated hyperfractionated radiotherapy for esophageal cancer:A meta-analysis［J］.Gansu Medical Journal,2014,33(11):888-894.［刘小峰,王小虎,张秋宁,等.后程加速超分割放射疗法治疗食管癌的Meta分析［J］.甘肃医药,2014,33(11):888-894.］
［15］Wei JH,Qiao LP.The effect of continuous accelerated hyperfractionated and late－course accelerated hyperfractionated radiotherapy on esophageal cancer：A Meta－analysis［J］.Chinese Journal of Gerontology,2016,36(7):1634-1636.［魏建宏,乔丽平.连续加速超分割放疗和后程加速超分割放疗治疗食管癌的Meta分析［J］.中国老年学杂志,2016,36(7):1634-1636.］
［16］Zhang DF,Wu QF,Ge CZ,et al.Clinical effect ofcisplatin plus5-FU chemotherapy combined with radiotherapy in the treatment of esophageal carcinoma［J］.Modern Oncology,2017,25(13):2061-2064.［张定富，吴秋芳，戈长征，等.顺铂联合5-FU化疗同步放疗治疗食管癌的临床效果［J］.现代肿瘤医学2017,25(13):2061-2064.］

Memo

Memo:
-
Last Update: 1900-01-01